Towards a Neurocognitive Profile of Post-Acute COVID-19: A Longitudinal Study Integrating Subjective Complaints and Computerized Cognitive Testing
Background/Objectives: The relationship between subjective cognitive complaints and objective performance in post-acute COVID syndrome (PACS), and the persistence of objective impairment over extended follow-up, remain unclear. This prospective longitudinal study characterized the neurocognitive profile of PACS […]
Cognitive impairment among patients with chronic immune thrombocytopenia
Immune thrombocytopenia (ITP) is an autoimmune disease typically associated with severely depleted platelet counts. However, additional symptoms (e.g. increased fatigue and memory/concentration difficulties) can profoundly impact patients’ quality of life. The nature and severity of cognitive […]
An evaluation of computerized attention and executive function measures for use with school age children with neurofibromatosis type 1
The present study investigated the performance of children with neurofibromatosis type 1 on computerized assessments of attention and executive function. Relations to ADHD symptomatology were also examined. Participants included 37 children (20 male) with NF1 (9-13 […]
A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M 1 receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer’s disease
Introduction: This study examined the safety and pharmacodynamic effects of selective muscarinic M1 receptor orthosteric agonist HTL0018318 in 60 patients with mild-to-moderate Alzheimer’s disease (AD) on background donepezil 10 mg/day. Methods: A randomized, double-blind, placebo-controlled 4-week […]
A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M 1 receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer’s disease
Introduction: This study examined the safety and pharmacodynamic effects of selective muscarinic M1 receptor orthosteric agonist HTL0018318 in 60 patients with mild-to-moderate Alzheimer’s disease (AD) on background donepezil 10 mg/day. Methods: A randomized, double-blind, placebo-controlled 4-week […]
